Literature DB >> 11551641

Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses.

P S Caufour1, M C Motta, A M Yamamura, S Vazquez, I I Ferreira, A V Jabor, M C Bonaldo, M S Freire, R Galler.   

Abstract

Chimeric yellow fever (YF)-dengue type 2 (Den 2) viruses were constructed by replacing the premembrane (prM) and envelope (E) genes of YF 17D virus with those from Den 2 virus strains of south-east Asian genotype. Whereas viable chimeric viruses were successfully recovered when the YF 17D C gene and the Den 2 prM gene were fused at the signalase cleavage site, no virus could be rescued from the constructions fused at the viral protease cleavage site. Unlike YF virus that replicated in all the cell lines tested and similar to the Den 2 virus, the recombinant viruses did not replicate in vaccine-production certified CEF and MRC5 cells. Besides, chimeric 17D/Den 2 viruses and their parental viruses reached similar growth titers in Vero and C6/36 cell cultures. Analysis of mouse neurovirulence, performed by intracerebral inoculation, demonstrated that the 17D/Den 2 chimera is more attenuated in this system than the YF 17DD virus. Immunization of mice with this chimera induced a neutralizing antibody response associated with a partial protection against an otherwise lethal dose of mouse neurovirulent Den 2 NGC virus. Overall, these results provide further support for the use of chimeric viruses as an attractive methodology for the development of new live flavivirus vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551641     DOI: 10.1016/s0168-1702(01)00273-8

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  24 in total

1.  Mouse norovirus 1 utilizes the cytoskeleton network to establish localization of the replication complex proximal to the microtubule organizing center.

Authors:  Jennifer L Hyde; Leah K Gillespie; Jason M Mackenzie
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.

Authors:  Myrna C Bonaldo; Richard C Garratt; Renato S Marchevsky; Evandro S F Coutinho; Alfredo V Jabor; Luís F C Almeida; Anna M Y Yamamura; Adriana S Duarte; Prisciliana J Oliveira; Jackeline O P Lizeu; Luiz A B Camacho; Marcos S Freire; Ricardo Galler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 4.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

5.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.

Authors:  Alexander G Pletnev; Robert Putnak; Jim Speicher; Eric J Wagar; David W Vaughn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

6.  Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Authors:  F Guirakhoo; J Arroyo; K V Pugachev; C Miller; Z X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Soike; M Ratterree; T P Monath
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.

Authors:  Stephen Tottey; Yoko Shoji; R Mark Jones; Jessica A Chichester; Brian J Green; Konstantin Musiychuk; Huaxin Si; Slobodanka D Manceva; Amy Rhee; Moneim Shamloul; Joey Norikane; Rosane C Guimarães; Elena Caride; Andrea N M R Silva; Marisol Simões; Patricia C C Neves; Renato Marchevsky; Marcos S Freire; Stephen J Streatfield; Vidadi Yusibov
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

8.  Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.

Authors:  Thomas J Chambers; Yan Liang; Deborah A Droll; Jacob J Schlesinger; Andrew D Davidson; Peter J Wright; Xiaoshan Jiang
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.

Authors:  Flavio Lauretti; Anasuya Chattopadhyay; Rafael Freitas de Oliveira França; Luiza Castro-Jorge; John Rose; Benedito A L da Fonseca
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.